Clinical Trial Update: Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating radioembolization combined with durvalumab for locally advanced, unresectable hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Radioembolization

Snippet

Sponsor: Seoul National University Hospital | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED